NIH-funded research R01 grant

Understanding how a protein called SHIP1 works in human immune cells

Official title: Deciphering the mechanism of SHIP1 regulation in human neutrophils

Funded at University of Oregon · NIH-11373379 · Data updated 2026-11-12

This research explores how human immune cells, specifically neutrophils, respond to signals in the body by studying a key protein called SHIP1.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Oregon
NIH-funded
Lab location1 site (Eugene, United States)
Project startJuly 1, 2021
Project endMay 31, 2026
Funding year2025
Award (this year)$77,777
NIH project number3R01GM143406-05S1
Project IDNIH-11373379 on NIH RePORTER

Who could benefit from this research

Could help

This foundational research is relevant to anyone interested in how their immune system works, particularly those with conditions involving neutrophil function or immune cell signaling.

Less likely to help

Patients will not receive direct medical benefit from participating in this basic science research, as it focuses on fundamental biological mechanisms.

What this research studies

Our immune cells, like neutrophils, constantly interpret chemical messages to decide how to act, such as moving towards an infection. This project aims to understand the complex communication between different signaling molecules within these cells, focusing on how a lipid phosphatase called SHIP1 helps control these responses. We are looking at how SHIP1 interacts with other molecules at the cell's surface and how it triggers a unique 'traveling wave' of signals. By using advanced techniques, we hope to uncover how SHIP1 is activated and how it influences the cell's ability to react to its environment.

Why it matters

Potential benefit: A deeper understanding of SHIP1's role in immune cell behavior could lead to new ways to treat conditions where immune responses are overactive or not strong enough.

How similar studies have gone: This project builds on existing knowledge of immune cell signaling, but it explores novel aspects of SHIP1's role and a unique 'excitable' signaling behavior within human neutrophils.

Where this research is happening

  • University of Oregon
    Eugene, United States
    Active

Researchers

  • Principal investigator: Hansen, Scott David — University of Oregon
  • Study coordinator: Hansen, Scott David

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.